JP5563835B2 - Method for producing aspirin tablets - Google Patents
Method for producing aspirin tablets Download PDFInfo
- Publication number
- JP5563835B2 JP5563835B2 JP2010006539A JP2010006539A JP5563835B2 JP 5563835 B2 JP5563835 B2 JP 5563835B2 JP 2010006539 A JP2010006539 A JP 2010006539A JP 2010006539 A JP2010006539 A JP 2010006539A JP 5563835 B2 JP5563835 B2 JP 5563835B2
- Authority
- JP
- Japan
- Prior art keywords
- aspirin
- tablet
- polyvinyl alcohol
- lubricant
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims description 55
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims description 55
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 27
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 21
- 239000000314 lubricant Substances 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 12
- 238000000576 coating method Methods 0.000 claims description 12
- 238000000748 compression moulding Methods 0.000 claims description 10
- 238000005469 granulation Methods 0.000 claims description 10
- 230000003179 granulation Effects 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000005507 spraying Methods 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 44
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 239000000203 mixture Substances 0.000 description 10
- 239000007921 spray Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229920002261 Corn starch Polymers 0.000 description 7
- 239000008120 corn starch Substances 0.000 description 7
- 239000004570 mortar (masonry) Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 238000004898 kneading Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 229920006254 polymer film Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229920003124 powdered cellulose Polymers 0.000 description 3
- 235000019814 powdered cellulose Nutrition 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- -1 sucrose fatty acid ester Chemical class 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- RRHDOBZTFMWNKM-UHFFFAOYSA-L [Cl-].[K+].[I+].[Cl-] Chemical compound [Cl-].[K+].[I+].[Cl-] RRHDOBZTFMWNKM-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229940068811 digitalis preparation Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- WRLGYAWRGXKSKG-UHFFFAOYSA-M phenobarbital sodium Chemical compound [Na+].C=1C=CC=CC=1C1(CC)C(=O)NC([O-])=NC1=O WRLGYAWRGXKSKG-UHFFFAOYSA-M 0.000 description 1
- 229960002511 phenobarbital sodium Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- JWBPVFVNISJVEM-UHFFFAOYSA-M sodium caffeine benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
- WSRBRQQGWDWSON-UHFFFAOYSA-M sodium;3,7-dimethylpurine-2,6-dione;2-hydroxybenzoate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O.CN1C(=O)NC(=O)C2=C1N=CN2C WSRBRQQGWDWSON-UHFFFAOYSA-M 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229920003170 water-soluble synthetic polymer Polymers 0.000 description 1
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、滑沢剤を使用することなく圧縮成形によりアスピリンの錠剤を製造する方法に関する。 The present invention relates to a method for producing aspirin tablets by compression molding without the use of a lubricant.
アスピリンは解熱鎮痛薬として汎用されてきた薬剤であり、近年においては、抗血小板剤としても注目され、狭心症、心筋梗塞、虚血性脳血管障害を予防するための、血栓・塞栓形成の抑制薬としての利用が拡大している薬剤である。 Aspirin is a drug that has been widely used as an antipyretic analgesic. In recent years, it has also attracted attention as an antiplatelet agent, and it suppresses thrombus and embolization to prevent angina pectoris, myocardial infarction, and ischemic cerebrovascular disorder. It is a drug that is expanding its use as a medicine.
反面、アスピリンは、加水分解しやすい、添加剤との配合変化が起きやすいなどの性質を有しており、製剤化においては困難が伴う薬物である。日本薬局方によれば、アスピリンは吸湿によって脱アセチル化が起こり、この際生じる酢酸が更に変化を促進すると記載されており、また、アスピリンは配合変化しやすい薬剤であり、アスピリンと配合した場合変化を起こす化合物として次の例が示されている。a)1週間以内に湿潤するもの:安息香酸ナトリウムカフェイン、サリチル酸ナトリウムテオブロミン、炭酸水素ナトリウム、ヘキサミン、b)1週間以内に変色するもの:ジギタリス製剤、ヨウ化物、c)品質、保存条件によって1週間以内に湿潤するもの:アミノ安息香酸エチル、アミノピリン、アンチピリン、スルピリン、d)品質、保存条件によって1週間以内に変色するもの:硫酸鉄、e)その他配合変化を起こす薬物:フェノバルビタールナトリウム、ヨウ化カリウム、酸、水酸化物、炭酸塩、ステアリン酸塩。 On the other hand, aspirin is a drug that is difficult to formulate because it has properties such as being easily hydrolyzed and easily changing its formulation with additives. According to the Japanese Pharmacopoeia, it is described that aspirin is deacetylated due to moisture absorption, and acetic acid generated at this time further promotes changes, and aspirin is a drug that is easy to change, and changes when combined with aspirin. The following examples are shown as compounds that cause a) Wet within one week: sodium caffeine benzoate, sodium theobromine salicylate, sodium bicarbonate, hexamine, b) Discolor within one week: digitalis preparation, iodide, c) 1 depending on quality and storage conditions Wet within a week: ethyl aminobenzoate, aminopyrine, antipyrine, sulpyrine, d) Discoloration within one week depending on quality and storage conditions: Iron sulfate, e) Other drugs that cause changes in formulation: Phenobarbital sodium, iodine Potassium chloride, acid, hydroxide, carbonate, stearate.
このように、アスピリンは加水分解しやすく、かつ多くの薬剤や製剤化用添加剤と配合変化を起こす性質を有しているため、限られた錠剤用添加剤を用い、乾式法により製剤化する方法が一般的になっているが、通常の臼杵を用いて圧縮製錠する場合、化学的に安定で、かつ臼杵への付着のない外観のよい素錠を製することは、製剤化技術的に非常に困難である。 In this way, aspirin is easily hydrolyzed and has the property of causing compounding changes with many drugs and formulation additives. Therefore, it is formulated by a dry method using limited tablet additives. Although the method has become common, in the case of compression tableting using a normal mortar, it is technically necessary to produce an uncoated tablet that is chemically stable and has good appearance without sticking to the mortar. It is very difficult.
アスピリン錠剤の場合、特に問題となるのは、滑沢剤(離型剤)である。市販されている医療用錠剤においては、大半の薬剤が、滑沢剤として、滑沢性の強いステアリン酸マグネシウム、ステアリン酸カルシウム、フマル酸ステアリルナトリウム、ステアリン酸などを配合して製造されているが、これらの滑沢剤はアスピリンとの配合変化があり、配合できない。そのためこれらに代ってタルクなどの代替品を使用することが考えられるが、タルク、硬化油、ショ糖脂肪酸エステルなどの代替品では圧縮成形時の臼杵への付着を満足に防止することができない。 In the case of an aspirin tablet, a lubricant (release agent) is particularly problematic. In the medical tablets that are commercially available, most drugs are manufactured as a lubricant by blending highly lubricated magnesium stearate, calcium stearate, sodium stearyl fumarate, stearic acid, etc. These lubricants cannot be blended because there are blending changes with aspirin. Therefore, it is conceivable to use substitutes such as talc instead of these, but substitutes such as talc, hydrogenated oil, and sucrose fatty acid ester cannot satisfactorily prevent adhesion to the mortar during compression molding. .
特開2009−89982号公報(特許文献1)には、打錠時臼杵へのスティッキングが発生し易い薬物の造粒物を高分子膜剤で被覆することにより、滑沢剤無添加で打錠障害なく容易に打錠できる造粒物の製造方法が記載されている。高分子膜剤としてポリビニルアルコールが使用されているが、薬物としてアスピリンは使用されていない。多くの実施例ではイブプロフェン等の薬物と軽質無水ケイ酸との混合粉末を造粒し、その造粒物の表面をポリビニルアルコールなどを水に溶解した液に、トウモロコシデンプンを懸濁した溶液を用いてスプレーし、被覆して得られた造粒物を乾燥し篩過した整粒品を用い、滑沢剤を添加することなく圧縮成形して錠剤を製造している。この方法がアスピリンに適用できることを示唆する記載はないが、この方法は薬物と軽質無水ケイ酸との混合粉末を造粒しながら高分子膜の水溶液を噴霧して被覆する湿式造粒法であるのに対し、軽質無水ケイ酸がアスピリンの加水分解を促進させる性質を有していること、およびアスピリン自体が加水分解されやすい性質を有していることから、この方法をアスピリンに転用することはできない。 JP-A-2009-89982 (Patent Document 1) discloses tableting without adding a lubricant by coating a granulated product of a drug that is likely to stick to a mortar during tableting with a polymer film agent. A method for producing a granulated product that can be easily tableted without hindrance is described. Polyvinyl alcohol is used as a polymer film agent, but aspirin is not used as a drug. In many embodiments, a mixed powder of a drug such as ibuprofen and light anhydrous silicic acid is granulated, and the surface of the granulated material is a solution obtained by suspending corn starch in a solution obtained by dissolving polyvinyl alcohol or the like in water. The granulated product obtained by spraying and coating is dried and sieved to obtain a tablet by compression molding without adding a lubricant. Although there is no description suggesting that this method can be applied to aspirin, this method is a wet granulation method in which an aqueous solution of a polymer film is sprayed and coated while granulating a mixed powder of a drug and light anhydrous silicic acid. On the other hand, since light anhydrous silicic acid has the property of promoting hydrolysis of aspirin, and aspirin itself has the property of being easily hydrolyzed, it is not possible to divert this method to aspirin. Can not.
従って本発明の課題は、滑沢剤を使用することなく圧縮成形によって錠剤に成形することができるアスピリン錠剤の製造方法を提供することである。 Therefore, the subject of this invention is providing the manufacturing method of the aspirin tablet which can be shape | molded by compression molding without using a lubricant.
本発明は、
a)アスピリンにポリビニルアルコール水溶液を噴霧して造粒し、乾燥する工程、および
b)得られた造粒物に、デンプンを主体とし任意に他の賦形剤を含む賦形成分を添加し、滑沢剤を添加することなく圧縮成形する工程よりなるアスピリン錠剤の製造方法を提供する。
The present invention
a) spraying aspirin with a polyvinyl alcohol aqueous solution to granulate and drying; and b) adding a formed component mainly comprising starch and optionally containing other excipients to the resulting granulated product, Provided is a method for producing an aspirin tablet comprising a step of compression molding without adding a lubricant.
アスピリン錠剤は、全重量の60%以上をアスピリンが占めることができる。 Aspirin tablets can account for 60% or more of the total weight.
好ましい具体例によれば、b)工程において水溶液として噴霧されるポリビニルアルコールの量は、アスピリンの0.5−3重量%であり、ポリビニルアルコールを噴霧してアスピリンを造粒する工程は流動層造粒コーティング装置を使用して実施される。 According to a preferred embodiment, the amount of polyvinyl alcohol sprayed as an aqueous solution in step b) is 0.5-3% by weight of aspirin, and the step of granulating aspirin by spraying polyvinyl alcohol is a fluidized bed construction. This is done using a grain coating machine.
薬物がアスピリンであること以外に、本発明方法が特許文献1に開示された先行技術と相違する点は造粒物が薬物と軽質無水ケイ酸との混合物ではないことである。軽質無水ケイ酸は、その名の示すとおり見掛けの比重が極めて小さい多孔性のシリカゲル粉末であり、多量の水を吸収して保持することおよびアスピリンとは配合禁忌であることから、極めて加水分解され易いアスピリンに配合すべきではない。しかしながらアスピリン単独にポリビニルアルコール水溶液を噴霧して造粒する場合は、水との接触時間が短時間であるため実質上加水分解は起こらない。 Aside from the fact that the drug is aspirin, the method of the present invention differs from the prior art disclosed in Patent Document 1 in that the granulated product is not a mixture of drug and light anhydrous silicic acid. Light silica is a porous silica gel powder whose apparent specific gravity is extremely small as its name suggests.It absorbs and retains a large amount of water and is incompatible with aspirin, so it is extremely hydrolyzed. Should not be incorporated into easy aspirin. However, in the case of granulating by spraying an aqueous solution of polyvinyl alcohol on aspirin alone, hydrolysis does not occur substantially because the contact time with water is short.
薬物と賦形剤等の混合物を粉末の状態で圧縮成形する直接打錠法にせよ、前記混合物を一旦顆粒に造粒した後圧縮成形する方法にせよ、錠剤への圧縮成形には通常滑沢剤の使用が必要である。滑沢剤を使用しなければ圧縮成形された錠剤の離型性が悪く、錠剤の表面の一部が欠け落ちて打錠用の杵や臼に付着し、円滑な打錠を妨げるほか、表面に欠陥のある不良錠剤が発生する。また、ロータリー式打錠機のターンテーブル表面に錠剤成型用の混合物が固く貼り付いて打錠できなくなるという問題も発生する。 Whether it is a direct tableting method in which a mixture of drugs and excipients is compression-molded in a powder state, or a method in which the mixture is once granulated and then compression-molded, compression molding into tablets is usually smooth. The use of an agent is necessary. Without the use of a lubricant, the release of compressed tablets is poor, and part of the tablet surface is chipped off and adheres to the tableting pestle and die, preventing smooth tableting and the surface. A defective tablet with defects is generated. In addition, there is a problem that the tablet-forming mixture is stuck firmly on the surface of the turntable of the rotary tableting machine and cannot be tableted.
アスピリンの場合、前述したように配合禁忌成分が非常に多く、滑沢剤として普通使用されているステアリン酸マグネシウム、ステアリン酸カルシウム、フマル酸ステアリルナトリウム、ステアリン酸などはアスピリンの化学的安定性を害するので使用できない。本発明者の知見によれば、アスピリンの化学的安定性に影響しないと考えられるタルクを滑沢剤として使用し、賦形剤としてトウモロコシデンプンとの混合物を乾式法によって圧縮成形し、アスピリン100mgを含有する1錠130mgの錠剤の製造を試みたところ、打錠機の杵と臼の表面に錠剤から欠け落ちた粉末が堅く付着し、表面に欠陥のない錠剤を得ることができなかった。同様にその他の滑沢剤として考えられるショ糖脂肪酸エステルおよび硬化油を滑沢剤として用いて同じテストを行ったが、好ましい結果は得られなかった。 In the case of aspirin, as mentioned above, there are a large number of contraindicated ingredients, and magnesium stearate, calcium stearate, sodium stearyl fumarate, stearic acid, etc., which are commonly used as lubricants, impair the chemical stability of aspirin. I can not use it. According to the knowledge of the present inventor, talc, which is considered not to affect the chemical stability of aspirin, is used as a lubricant, a mixture with corn starch as an excipient is compression-molded by a dry method, and 100 mg of aspirin is added. When an attempt was made to produce a tablet of 130 mg containing it, the powder that had fallen off from the tablet adhered firmly to the surface of the punch and mortar of the tableting machine, and it was not possible to obtain a tablet with no defects on the surface. Similarly, the same test was carried out using sucrose fatty acid ester and hydrogenated oil, which are considered as other lubricants, as lubricants, but no favorable results were obtained.
本発明方法はポリビニルアルコールの水溶液を使用するので一種の湿式造粒法を使用する。しかしながらポリビニルアルコール水溶液は薬物と賦形剤等の補助剤の混合物を造粒するための結合液としてではなく、むしろアスピリン粒子の表面をポリビニルアルコールでコーティングするために使用される。ポリビニルアルコールによるコーティングの結果、アスピリン粒子の表面が改質され、滑沢剤を使用しなくても杵や臼へ付着のない造粒物が得られることがわかった。また、圧縮成形の際に、デンプンを主体とする賦形剤を造粒物に添加することにより、僅かではあるが滑沢作用があるデンプンが圧縮成形した錠剤の離型性並びに打錠機のターンテーブルへの打錠用混合物の固着防止を増強するものと考えられる。 Since the method of the present invention uses an aqueous solution of polyvinyl alcohol, a kind of wet granulation method is used. However, the aqueous polyvinyl alcohol solution is not used as a binding liquid for granulating a mixture of an agent such as a drug and an excipient, but rather is used to coat the surface of aspirin particles with polyvinyl alcohol. As a result of coating with polyvinyl alcohol, it was found that the surface of the aspirin particles was modified, and a granulated product having no adhesion to the pestle or mortar was obtained without using a lubricant. In addition, by adding an excipient mainly composed of starch to the granulated product at the time of compression molding, the release property of the tablet formed by compression molding of the starch having a slight lubricating action and the tableting machine This is thought to enhance the prevention of the tableting mixture from adhering to the turntable.
医薬品の製剤技術分野では、メチルセルロース、ヒドロキシプロピルセルロース、ヒプロメロース、CMCなどの水溶性セルロース誘導体、ポリビニルアルコール、ポビドンなどの水溶性合成高分子などが結合剤として使用される。このうちポリビニルアルコールのみが滑沢性に富むコーティング膜を形成することがわかった。 In the pharmaceutical preparation technical field, water-soluble cellulose derivatives such as methylcellulose, hydroxypropylcellulose, hypromellose and CMC, water-soluble synthetic polymers such as polyvinyl alcohol and povidone, and the like are used as binders. Of these, only polyvinyl alcohol was found to form a coating film rich in lubricity.
先に述べたように、ポリビニルアルコールでコーティングされたアスピリンの造粒物を錠剤に圧縮成形する際に、デンプンを主体とする賦形剤を添加することにより錠剤の離型性がさらに増強される。ここで使用されるデンプンは、例えばトウモロコシデンプン、バレイショデンプン、加工デンプンなどである。デンプンを主体とし、乳糖、ブドウ糖、マンニトール、ソルビット、粉末セルロースなどの糖および糖アルコールや、デンプン以外の多糖類を併用してもよい。 As described above, when a granulated aspirin coated with polyvinyl alcohol is compressed into a tablet, the release property of the tablet is further enhanced by adding an excipient based on starch. . Examples of the starch used here include corn starch, potato starch, and modified starch. Starch is mainly used, and sugars such as lactose, glucose, mannitol, sorbitol, and powdered cellulose, sugar alcohols, and polysaccharides other than starch may be used in combination.
本発明に従って製造される錠剤は、通常錠剤全重量の60%以上、好ましくは70%以上、最も好ましくは80%以上のアスピリンを含んでいる。残余はポリビニルアルコールと、賦形剤等の補助剤が占める。そのうちポリビニルアルコールは、アスピリンの重量を基準にして、0.5−3%、好ましくは2%までで十分である。過剰に被覆すると崩壊性に悪影響を及ぼす。 Tablets produced in accordance with the present invention typically contain 60% or more of the total weight of the tablet, preferably 70% or more, most preferably 80% or more of aspirin. The remainder is occupied by polyvinyl alcohol and adjuvants such as excipients. Of these, polyvinyl alcohol is sufficient up to 0.5-3%, preferably up to 2%, based on the weight of aspirin. Excessive coating adversely affects disintegration.
なお、上記成分のほか微量の慣用添加剤の配合は任意である。 In addition to the above components, the addition of a trace amount of conventional additives is optional.
ポリビニルアルコールで表面改質を行ったものであっても、タルクなどの滑沢剤を配合して圧縮成形を行った場合、作業開始当初は杵面への錠剤の付着はないが、圧縮成形の時間経過とともに、徐々に杵表面への固着物の貼り付きが生じ、長時間に亘って臼杵からの離型性のよい、表面の美麗な錠剤を得ることはできなかった。これは時間の経過と共に、加圧圧縮によるアスピリンと滑沢剤との直接接触を要因とし、加圧圧縮時に発生する熱のために、滑沢剤がアスピリンを変性させて微量の分解物を発生させ、これが原因となり杵への微量成分の付着が始まり、この付着量が時間の経過と共に少しずつ増大し、遂には明らかな杵面への付着物の固着となる現象によるためと考えられる。 Even when the surface is modified with polyvinyl alcohol, when compression molding is performed with a lubricant such as talc, there is no adhesion of the tablet to the surface at the beginning of the work, As time passed, sticking matter gradually adhered to the surface of the heel, and it was not possible to obtain a tablet with a good surface and good release properties from the mortar over a long period of time. This is due to the direct contact between the aspirin and the lubricant due to pressure compression over time, and the lubricant denatures the aspirin due to the heat generated during pressure compression and generates a small amount of decomposition products. This is considered to be due to the phenomenon that the trace component starts to adhere to the soot due to this phenomenon, and the amount of this deposit gradually increases with the passage of time, and finally the adherent matter adheres to the well.
本錠剤を製造する方法は湿式法であるが、アスピリンの表面がポリビニルアルコールによって被覆されアスピリンの表面特性が隠蔽されることが肝要であるから、造粒方法の際には、アスピリンに、ポリビニルアルコールを水に溶解した溶液をスプレーしてコーティング造粒して、アスピリン表面にポリビニルアルコールを付着させるように操作することが必須である。本法を採用することにより、アスピリン表面がポリビニルアルコールによって被覆され滑沢性のある表面へと改質され好結果が得られる。 Although the method for producing the tablet is a wet method, it is important that the surface of aspirin is covered with polyvinyl alcohol so that the surface properties of the aspirin are concealed. It is essential to spray and apply a solution in which water is dissolved in water to make the polyvinyl alcohol adhere to the surface of the aspirin. By adopting this method, the surface of aspirin is coated with polyvinyl alcohol and modified to a smooth surface, and good results are obtained.
このコーティング的噴霧造粒においては、噴霧コーティングできる装置なら何でも利用できるが、乾燥効率が優れ、作業効率のよい装置が好ましく、その観点から流動層造粒コーティング装置が最良である。 In this coating type spray granulation, any apparatus capable of spray coating can be used. However, an apparatus having excellent drying efficiency and good working efficiency is preferable, and from this viewpoint, a fluidized bed granulation coating apparatus is the best.
混練造粒、捏和造粒、撹拌造粒などの練合方式の造粒法では、練合操作中にアスピリンがポリビニルアルコール溶液に溶解し、結果として造粒された粉粒体表面にポリビニルアルコールとアスピリンが混在して露出することになるため、アスピリンの表面改質は達成されず目的とする効果は低減する。 In kneading granulation methods such as kneading granulation, kneading granulation, and stirring granulation, aspirin dissolves in the polyvinyl alcohol solution during the kneading operation, and as a result, the surface of the granulated granule is polyvinyl alcohol. Since aspirin is exposed in a mixed manner, surface modification of aspirin is not achieved and the intended effect is reduced.
以下に限定を意図しない実施例などによって、本発明を例証する。 The invention is illustrated by the following non-limiting examples.
〔実施例1〕
ポリビニルアルコール96gを水2304gに溶解した。アスピリンを8kgとり流動層造粒機(フロイント産業製、FLO−15)に仕込み、この液を用いて、トップスプレー法にてコーティング的な造粒を行い(噴霧液量:50mL/min、噴霧空気圧:0.25MPa、給気温度:60℃、排気温度:28.5〜36.2℃)、アスピリン粒子を得た。この粒子に、粉末セルロース784g、無水トウモロコシデンプン960gを混合し、直径7.0mm、7.5Rの杵を用い、12本立てロータリー打錠機で1錠重量123mgに加圧圧縮して錠剤を製したところ、錠剤の杵への付着は観察されず、外観のよい錠剤(錠剤硬度:60N)が得られた。また、この錠剤をガラス瓶に入れ、密栓して60℃に1週間保存した錠剤のサリチル酸含量は、約0.2mg/Tab(初期値:約0.1mg/Tab)であり、安定な錠剤であることがわかった。
[Example 1]
96 g of polyvinyl alcohol was dissolved in 2304 g of water. 8kg of aspirin is taken into a fluidized bed granulator (Freund Sangyo, FLO-15), and this solution is used for coating granulation by the top spray method (amount of spray liquid: 50 mL / min, spray air pressure) : 0.25 MPa, supply air temperature: 60 ° C., exhaust temperature: 28.5-36.2 ° C.), and aspirin particles were obtained. The particles were mixed with 784 g of powdered cellulose and 960 g of anhydrous corn starch, and compressed into a tablet weight of 123 mg using a 12-piece rotary tablet press using a 7.0 mm diameter and 7.5 R pestle to produce a tablet. However, no adhesion of the tablets to the wrinkles was observed, and tablets with good appearance (tablet hardness: 60 N) were obtained. Moreover, the salicylic acid content of the tablet stored in a glass bottle, sealed and stored at 60 ° C. for 1 week is about 0.2 mg / Tab (initial value: about 0.1 mg / Tab), which is a stable tablet. I understood it.
〔実施例2〕
ポリビニルアルコール100gを水2400gに溶解した。アスピリンを14.3kgとり流動層造粒機(フロイント産業製、FLO−15)に仕込み、この液を用いて、トップスプレー法にてコーティング的な造粒を行い(噴霧液量:120mL/min、噴霧空気圧:0.25MPa、給気温度:60℃、排気温度:21.3〜29.4℃)、アスピリン粒子を得た。この粒子に、粉末セルロース1.22kg、無水トウモロコシデンプン1.64kgを混合し、直径7.0mm、7.5Rの杵を用い、12本立てロータリー打錠機で1錠重量120.7mgに加圧圧縮して錠剤を製したところ、錠剤の杵への付着は観察されず、外観のよい錠剤(錠剤硬度:65.8N)が得られた。また、この錠剤をガラス瓶に入れ、密栓して60℃に1週間保存した錠剤のサリチル酸含量は、約0.2mg/Tab(初期値:約0.1mg/Tab)であり、安定な錠剤であることがわかった。
[Example 2]
100 g of polyvinyl alcohol was dissolved in 2400 g of water. 14.3 kg of aspirin was taken and charged into a fluidized bed granulator (Freund Sangyo, FLO-15), and this solution was used for coating granulation by the top spray method (amount of spray liquid: 120 mL / min, Spraying air pressure: 0.25 MPa, supply air temperature: 60 ° C., exhaust temperature: 21.3-29.4 ° C.), aspirin particles were obtained. This particle is mixed with 1.22 kg of powdered cellulose and 1.64 kg of anhydrous corn starch, and compressed with a 12-piece rotary tableting machine to 120.7 mg using a 12 mm diameter rotary tableting machine. As a result, tablets were not observed to adhere to the wrinkles, and tablets with good appearance (tablet hardness: 65.8 N) were obtained. Moreover, the salicylic acid content of the tablet stored in a glass bottle, sealed and stored at 60 ° C. for 1 week is about 0.2 mg / Tab (initial value: about 0.1 mg / Tab), which is a stable tablet. I understood it.
〔比較例1〕
ポリビニルアルコール120gを水2880gに溶解した。アスピリンを12kg、無水トウモロコシデンプンを960gとり流動層造粒機(フロイント産業製、FLO−15)に仕込み、この液を用いて、トップスプレー法にてコーティング的な造粒を行い(噴霧液量:100mL/min、噴霧空気圧:0.25MPa、給気温度:60℃、排気温度:23.7〜32.2℃)、アスピリン粒子を得た。この粒子に、無水トウモロコシデンプン960g、タルク960gを混合し、直径7.0mm、7.5Rの杵を用い、12本立てロータリー打錠機で1錠重量125mgに加圧圧縮して錠剤を製したところ、徐々に錠剤の杵への付着が発生し、錠剤表面にくぼみが観察されるようになり、最後まで外観のよい錠剤を得ることはできなかった。なお、錠剤硬度は60.6Nで、錠剤強度に問題はなかった。
[Comparative Example 1]
120 g of polyvinyl alcohol was dissolved in 2880 g of water. 12 kg of aspirin and 960 g of anhydrous corn starch are taken into a fluidized bed granulator (Freund Sangyo Co., Ltd., FLO-15), and this solution is used for coating granulation by the top spray method (amount of spray liquid: 100 mL / min, spraying air pressure: 0.25 MPa, supply air temperature: 60 ° C., exhaust temperature: 23.7-32.2 ° C.), aspirin particles were obtained. When 960 g of anhydrous corn starch and 960 g of talc are mixed with these particles, a tablet having a diameter of 7.0 mm and 7.5 R is pressed and compressed into a tablet weight of 125 mg using a 12-piece rotary tablet press. Gradually, the tablet was attached to the wrinkles, and dents were observed on the surface of the tablet, and it was impossible to obtain a tablet with a good appearance until the end. The tablet hardness was 60.6 N, and there was no problem in tablet strength.
Claims (4)
b)得られた造粒物に、デンプンを主体として任意の他の賦形剤を含む賦形成分を添加し、滑沢剤を添加することなく圧縮成形する工程よりなるアスピリン錠剤の製造方法。 a) Step of spraying and granulating an aspirin with an aqueous solution containing 0.5 to 3% by weight of polyvinyl alcohol of aspirin as a solid content and drying, and b) The resulting granulated product mainly comprising starch. A method for producing an aspirin tablet comprising a step of adding a forming component containing any other excipient and compression molding without adding a lubricant.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010006539A JP5563835B2 (en) | 2010-01-15 | 2010-01-15 | Method for producing aspirin tablets |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010006539A JP5563835B2 (en) | 2010-01-15 | 2010-01-15 | Method for producing aspirin tablets |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011144137A JP2011144137A (en) | 2011-07-28 |
JP5563835B2 true JP5563835B2 (en) | 2014-07-30 |
Family
ID=44459329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010006539A Active JP5563835B2 (en) | 2010-01-15 | 2010-01-15 | Method for producing aspirin tablets |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5563835B2 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1120111T3 (en) * | 1998-10-07 | 2008-03-10 | Kyowa Hakko Kogyo Kk | Method for stabilizing an active substance in a tablet |
DE10202019A1 (en) * | 2002-01-18 | 2003-07-24 | Bayer Ag | Pharmaceutical composition, useful in oral formulations for the treatment of e.g. rheumatism, neuralgia, migraine or myocardial infarction, comprises a free-flowing salt of acetylsalicylic acid and a basic amino acid |
JP2009089982A (en) * | 2007-10-11 | 2009-04-30 | Ohara Yakuhin Kogyo Kk | Method of granular material for making tablets |
-
2010
- 2010-01-15 JP JP2010006539A patent/JP5563835B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2011144137A (en) | 2011-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6195957B2 (en) | Composite granulated product and immediate release preparation containing low-substituted hydroxypropylcellulose | |
JP5446716B2 (en) | Method for producing tablets containing arginine and carnitine | |
JP5798642B2 (en) | Oral pharmaceutical composition | |
JP5517327B2 (en) | Composition for orally disintegrating tablets | |
CN102196811B (en) | Stable tablet containing 4,5-epoxymorphinan derivative | |
JP6126456B2 (en) | Granules for tableting and production method thereof, orally disintegrating tablets using the granules for tableting | |
JP2010189384A (en) | Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose | |
JP6307417B2 (en) | Composite granulated product, immediate-release tablet and production method thereof | |
JPWO2007123021A1 (en) | Method for producing sustained-release tablets | |
JP5563835B2 (en) | Method for producing aspirin tablets | |
JP2006143650A (en) | Method for producing tablet containing medicine having high adhesiveness | |
JP5454162B2 (en) | Film-coated solid preparation containing sublimable component | |
JP2013203690A (en) | Intraorally disintegrating tablet and method for producing the same | |
CA2760068A1 (en) | Retigabine tablets, preferably with modified release | |
JP7419057B2 (en) | Tablets and coated tablets | |
JP4934314B2 (en) | Method for producing stable sarpogrelate hydrochloride-containing tablets | |
JP7274825B2 (en) | Tablet and its manufacturing method | |
JP6407085B2 (en) | Tablet and production method thereof | |
JP6552088B2 (en) | Granulated granules and method for producing the same, tablet and method for producing the same | |
JP6180382B2 (en) | Tablet and production method thereof | |
JP6004524B2 (en) | Method for producing clopidogrel sulfate-containing tablets | |
JP7241468B2 (en) | Tablets and coated tablets, and methods for producing them | |
JP2017132717A (en) | Layered tablet and method for producing the same | |
JP6037824B2 (en) | Etodolac-containing solid preparation | |
JP2009167110A (en) | Sarpogrelate hydrochloride-containing oral preparation excellent in stability in unpacked state |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20121207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140218 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140312 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140610 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140613 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5563835 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |